Research program for people with sickle cell disease on hydroxyurea
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of sickle cell disease (any genetic type).
- You are being seen at St. Jude Children’s Research Hospital and can enroll in the parent research program.
- If you join the hydroxyurea part, you are currently taking hydroxyurea and have reached the maximum tolerated dose.
- You have stayed on that same hydroxyurea dose for at least 90 days before enrollment.
- You (or your parent/guardian) can give written informed consent and agree to follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial checks whether monitoring hydroxyurea drug levels in the blood can help doctors find the best dose for sickle cell patients. It focuses on people with HbSS who have recently had a pain crisis or whose current dose isn't working.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
This study helps doctors personalize hydroxyurea treatment for people with sickle cell disease of Nigerian descent by looking at how your body processes the medication. The goal is to find the dose that works best for you with fewer side effects.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.